>
Switch to:

ITeos Therapeutics Earnings Yield (Joel Greenblatt) %

: -10.95% (As of Jun. 2021)
View and export this data going back to 2020. Start your Free Trial

ITeos Therapeutics's Enterprise Value for the quarter that ended in Jun. 2021 was $601.67 Mil. ITeos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-65.87 Mil. ITeos Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2021 was -10.95%.

The historical rank and industry rank for ITeos Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

NAS:ITOS' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -15.76   Med: 0   Max: 0
Current: -9.62

-15.76
0
NAS:ITOS's Earnings Yield (Joel Greenblatt) % is ranked lower than
99.99% of the 279 Companies
in the Biotechnology industry.

( Industry Median: -14.30 vs. NAS:ITOS: -9.62 )

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. ITeos Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2021 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


ITeos Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for ITeos Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ITeos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20
Earnings Yield (Joel Greenblatt) %
- - -4.63

ITeos Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Earnings Yield (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -5.91 -4.63 -5.29 -10.95

Competitive Comparison

For the Biotechnology subindustry, ITeos Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

ITeos Therapeutics Earnings Yield (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where ITeos Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.



ITeos Therapeutics Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

ITeos Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2020 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-39.307/848.889136
=-4.63 %

ITeos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.87 Mil.



ITeos Therapeutics  (NAS:ITOS) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


ITeos Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


ITeos Therapeutics Business Description

ITeos Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2833
Comparable Companies
Traded in Other Exchanges
N/A
Address
139 Main Street, Cambridge, MA, USA, 02142
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Executives
Evnin Luke 10 percent owner THE JOHN HANCOCK TOWER 200 CLARENDON STREET, 54TH STREET BOSTON MA 02116
Mpm Bioventures 2018 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018 Gp Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Asset Management Investors Bv2018 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018 (b), L.p. 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 Gp Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Asset Management Investors Bv2014 Llc 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 (b), L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02124
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Oncology Impact Fund (cayman) Management L.p. other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Oncology Impact Management Gp Llc other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Ubs Oncology Impact Fund L.p. other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Davis Aaron I. director, 10 percent owner 11682 EL CAMINO REAL, SUITE 320 SAN DIEGO CA 92130

ITeos Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)